Immunome was founded to advance the discovery and development of antibody-based drugs. Our proprietary antibody Discovery Engine identifies novel therapeutic antibodies, and their antigen targets, by leveraging the most highly-educated components of the B cells from patients who have learned to fight off their disease.
The strengths of Immunome’s Antibody Discovery Engine are the unbiased, broad, deep, and efficient manner with which it directly interrogates human B cells. This provides a better understanding of how the body itself recognizes and overcomes disease. In this way, the Immune Discovery Engine is able to efficiently identify the antibodies with the highest potential to address cancer and infectious diseases. This approach also allows Immunome to circumvent the weaknesses, complications and inefficiencies associated with conventional approaches. We believe that the antibodies we identify, which are already credentialed by the patient, are ideal for development.
A differentiated platform with strengths that enable the discovery of novel antibody-antigen pairs. Immunome’s technology allows us to move directly from the interrogation of the human B cell to large amounts of antibodies needed for function-based screening. To date, we have interrogated more than 150 patient samples and produced >250,000 hybridomas from patients with various cancers and infectious diseases.
